A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222

In the era of globally predominant omicron strains, a COVID-19 booster vaccine is needed. Our study aimed to evaluate the immunogenicity of a half-dose BNT162b2 booster after AZD1222 in healthy adults. A randomized trial of volunteers aged 18–69 years who received two-dose AZD1222 was conducted. The...

Full description

Bibliographic Details
Main Authors: Rapisa Nantanee, Watsamon Jantarabenjakul, Peera Jaru-Ampornpan, Pimpayao Sodsai, Orawan Himananto, Jitthiwa Athipunjapong, Jiratchaya Sophonphan, Sira Nanthapisal, Nattiya Hirankarn, Thanyawee Puthanakit
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/10/6/914